Researchers dive into why scleroderma and lung hypertension weaken the heart
NCT ID NCT04610788
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 43 adults with scleroderma or unexplained pulmonary arterial hypertension (PAH) to understand why the right side of the heart weakens. Researchers collected blood and tissue samples during routine procedures and measured heart function over 6 months. The goal was to learn how standard PAH treatment affects the heart, not to test a new therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Johns Hopkins
Baltimore, Maryland, 21287, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a skin patch ease stomach pain in scleroderma?
- Blood thinner may stop autoimmune disease before it starts
- Can online therapy help scleroderma patients manage daily life?
- Pandemic stress hits hard for arthritis patients
- New shot aims to tame rare autoimmune disease
- Can bosentan reverse lung artery thickening? small study investigates